Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 370 participants.
Also called NCT03080883
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 370 participants
- Registry
-
NCT03080883
-
- Other papers using this trial's data
- Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03080883. Randomized; double masking; primary purpose prevention. Start 2017-07-14 (actual); primary completion 2022-06-07 (actual). Results posted on 2023-12-12.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
- Condition
- Cerebral Vein Thrombosis
- Condition
- Deep Vein Thrombosis
- Condition
- Hematopoietic and Lymphoid Cell Neoplasm
- Condition
- Malignant Solid Neoplasm
- Condition
- Metastatic Malignant Solid Neoplasm
- Condition
- Pulmonary Embolism
- Condition
- Splanchnic Vein Thrombosis
- Intervention (Drug)
- Apixaban
- Lead sponsor
- Academic and Community Cancer Research United
- Collaborator
- National Cancer Institute (NCI)
Record details
- Record id
cardio:ct-nct03080883- Content hash
66f22df3ebbee116580aab796a2265012d8a22a4f07c2f41700c7baabe2a544d